🇺🇸

US SEC Filing Intelligence

· daily

Insider Trading Pulse — August 13, 2026

The insider trading digest for August 13, 2026 reveals a pronounced divergence between insider buying and selling. Buying activity is concentrated in companies like 51Talk, Amrize, and Embecta, where executives are deploying significant capital, often at prices near 52-week lows, signaling strong conviction. Conversely, selling is dominated by Sea Ltd, where multiple C-suite executives, including the CEO, have sold large blocks under Rule 10b5-1 plans, raising concerns about growth sustainability. The data also highlights a cluster of insider purchases in the healthcare and tech sectors, while financials show mixed activity with some notable sales. Period-over-period comparisons, where available, indicate that companies with insider buying are often experiencing revenue growth or margin improvements, while those with selling face margin compression or regulatory headwinds. Overall, the digest suggests selective opportunities in beaten-down names with insider support, but caution around high-flying tech and financial stocks with insider profit-taking.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 13, 2026

The latest batch of 11 filings from Dow 30 constituents reveals a notable pattern of insider selling, particularly at Merck and Chevron, where executives have realized significant gains. While most insider transactions are routine or tax-related, the magnitude of sales at Merck (over $10M by the General Counsel) and Chevron's New Energies President (exercising options and selling) warrants attention. The filings lack forward-looking guidance or period-over-period financial comparisons, limiting trend analysis. However, the insider activity suggests a cautious stance among some executives, potentially signaling near-term valuation concerns. The absence of major capital allocation events (dividends, buybacks) or M&A activity indicates a quiet period for these blue-chip firms. The overall sentiment is mixed, with neutral tax-withholding transactions at Walmart and UnitedHealth offsetting the negative signals from Merck and Chevron. The most critical development is the concentrated insider selling in the healthcare and energy sectors, which could be a leading indicator of sector rotation or profit-taking at perceived highs.

9 high priority 2 medium 11 total filings
· daily

Global High-Priority Regulatory Events — August 13, 2026

This digest covers 50 regulatory filings from August 13, 2026, dominated by distress and restructuring in Indian markets, alongside significant M&A activity in the US. Key themes include a wave of insolvencies (Cerebra, RCOM, Premier, Quadrant, Baron Infotech) and going-concern uncertainties (SAB Events, Leel Electricals), signaling a stressed credit environment. On the M&A front, two mega-deals closed: Parker-Hannifin's $9.25B acquisition of Filtration Group and Global Net Lease's $535M acquisition of Modiv Industrial, both immediately accretive. Insider activity was sparse, but notable was a promoter group entity increasing its stake in OBCL Limited by ~0.75% via open market purchases. Forward-looking statements highlight a catalyst-rich period, with several NCLT hearings and shareholder meetings scheduled in September 2026. The overall sentiment is bearish for distressed Indian entities and cautiously bullish for US industrial consolidation plays.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — August 13, 2026

The August 13, 2026 SEC filing batch reveals a market bifurcated between operational improvements and persistent financial stress. While several companies (Liftoff Mobile, Global Water Resources, Nuveen Global Cities REIT) posted strong YoY revenue and earnings growth, others (King Resources, Provectus Biopharmaceuticals) continue to burn cash with widening losses. Institutional 13F filings show a pronounced rotation into mega-cap tech and AI-related names, with notable new positions in Arm Holdings and Climb Bio, while hedge funds like Saba Capital trimmed passive stakes. Capital allocation trends highlight aggressive share repurchases at Nuveen Global Cities REIT despite net redemptions, and a shift toward debt-funded growth at Star Mountain. Insider activity is sparse, but the reduction in AQR's stake in Ultragenyx and Saba's cut in Voya Asia Pacific signal cautious sentiment. Forward-looking catalysts include upcoming earnings calls and potential FDA decisions, with the market closely watching guidance revisions and liquidity positions.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 13, 2026

The four filings from S&P 500 Consumer Discretionary constituents reveal a mixed sector picture, with insider activity and capital allocation providing the most actionable signals. A notable divergence in management sentiment is evident: Booking Holdings' CFO executed a significant, pre-planned stock sale of ~$1.79M, a bearish signal from a key insider, while Aptiv's CEO made a large gift of 51,190 shares, which is neutral but reduces his direct stake. Marriott's 8-K filing was a procedural placeholder with no material event, offering no new investment signal. In contrast, Ford Motor Credit's $2.5B debt offering strengthens liquidity but adds fixed interest costs, a neutral development for the parent company's financial health. No period-over-period trends or forward-looking guidance were disclosed in these filings, limiting trend analysis. The key takeaway is a cautious insider posture at Booking Holdings, which warrants monitoring, while Ford's capital markets activity signals a focus on funding operations through debt.

2 high priority 2 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 13, 2026

The S&P 500 Healthcare sector is showing a clear pattern of insider selling, with four senior executives from Thermo Fisher Scientific, Merck & Co., Abbott Laboratories, and Amgen collectively liquidating over $21 million in stock. This concentrated selling, often executed under 10b5-1 plans or following option exercises, suggests a period of profit-taking or portfolio rebalancing rather than outright alarm, but the volume and breadth warrant attention. The only positive institutional signal comes from Vanguard's increased passive stake in CVS Health, rising to 9.6% from 9.3% year-over-year, indicating continued index-driven accumulation. No forward-looking guidance, period-over-period financial comparisons, or capital allocation changes were reported in these filings, limiting the ability to assess operational trends. The lack of bullish insider activity and the absence of any buyback or dividend announcements create a cautious near-term outlook for the sector. Investors should monitor upcoming earnings calls for any management commentary that could explain the selling patterns.

6 high priority 2 medium 8 total filings
· daily

US Earnings Financial Results SEC Filings — August 13, 2026

The 50 filings for the period ending August 13, 2026, reveal a market bifurcated between a handful of high-growth, capital-intensive companies executing major IPOs and a broad base of micro-cap firms struggling with cash burn, revenue declines, and widening losses. Key period-over-period trends show a stark contrast: revenue growth at companies like X-Energy (+132% YoY) and Jones Soda (+108% YoY) is driven by new product lines and government contracts, while others like Classover Holdings (-34% YoY) and King Resources (revenue to zero) face severe top-line contraction. A critical portfolio-level pattern is the aggressive use of equity financing—Elmet Group and X-Energy raised a combined $1.2B through IPOs, while several others (Energous, Provectus) relied on at-the-market offerings and convertible notes to stay afloat. Margin compression is a dominant theme, with Energous Corp's gross margin collapsing from 35% to 3% and Elmet Group swinging from a $3.2M operating profit to a $7.6M loss, driven by stock-based compensation and rising G&A. Insider activity is sparse but notable, with several CEOs holding significant positions and no major insider selling detected, suggesting management conviction despite operational challenges. The most critical development is the successful IPOs of X-Energy and Elmet Group, which have transformed their balance sheets and positioned them for aggressive growth, while the persistent cash burn at companies like Global-Smart.Tech (cash down 99% to $81) and Alexander Tech (zero revenue, reliant on related-party loans) signals imminent distress.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 13, 2026

This digest of 8 proxy filings reveals a mixed landscape for executive compensation and governance. While General Mills shows a 12.2% CEO pay increase amid a stock price decline, Culp Inc. demonstrates compensation restraint with a continued base salary freeze for executives. The filings are dominated by routine governance matters, including director elections, auditor ratifications, and say-on-pay votes, with limited period-over-period financial data. A notable trend is the prevalence of virtual-only annual meetings and staggered board structures, particularly in smaller-cap companies like Remora Capital and urban-gro. SideChannel's proposal to drastically reduce authorized shares stands out as a significant capital structure event, while Old Westbury Funds and Worthington Enterprises present standard governance updates. The lack of robust financial performance data in most filings limits deep trend analysis, but the compensation patterns and governance proposals offer actionable insights for investors focused on shareholder rights and management alignment.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 13, 2026

The IPO Pipeline stream for August 13, 2026, features two distinct capital markets events: Rocket Lab's transformative S-4 merger with Iridium Communications and BayFirst Financial's S-1 resale registration. Rocket Lab's acquisition is a high-materiality strategic consolidation, creating a vertically integrated space company with a global satellite network, while BayFirst's filing is a routine resale registration with no new capital raised. Both filings signal active capital markets activity, with Rocket Lab's deal representing a significant catalyst for the space sector and BayFirst's registration indicating potential overhang from a recent private placement. The absence of traditional IPO pricing data in these filings limits period-over-period trend analysis, but the strategic and structural details provide actionable insights for investors.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — August 13, 2026

The August 13, 2026, executive and director change filings reveal a market characterized by significant leadership churn in the biotech and financial services sectors, with a notable number of departures lacking clear succession plans or stated reasons. A key theme is the use of performance-based compensation to retain top talent, as seen with Agenus and OnKure, while several companies like Zenas BioPharma and Marqeta face leadership vacuums that introduce operational uncertainty. The most critical development is the CFO transition at Zenas BioPharma, which coincides with a pivotal FDA PDUFA date for its lead drug, creating a high-stakes situation. Across the filings, the lack of transparency in many officer changes (e.g., Marqeta, BNY Mellon) is a recurring governance concern, while the appointment of high-profile directors at Sprinklr and Welsbach Technology Metals signals strategic pivots toward AI and defense logistics. Overall, the digest points to a bifurcated market where companies with clear succession plans and strong insider alignment are better positioned than those with abrupt departures and opaque disclosures.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 13, 2026

The August 13, 2026 batch of 23 SEC filings reveals a heavy concentration of routine governance changes, but several high-signal events stand out. The most critical development is Zenas BioPharma's CFO transition and its pivotal PDUFA date for obexelimab, creating a binary catalyst. A clear pattern of insider confidence is emerging: Agenus CEO Garo Armen accepted a high-performance stock option award with a 3x-8x strike price premium, signaling strong conviction, while OnKure Therapeutics repriced underwater options to retain talent, indicating internal pressure. Conversely, the sudden departures of Marqeta's CFO and GrabAGun's CEO without named successors or stated reasons are significant governance red flags. Across the board, the biotech sector shows a bifurcation between well-capitalized firms with clear catalysts (Zenas, Olema) and those with opaque leadership changes (Adial, Omeros). The appointment of a top AI executive from Microsoft to Sprinklr's board is a notable strategic hire, while the CFO-to-CEO transition at Magnolia Bancorp raises concerns about leadership depth at a small financial institution. Overall, the digest points to a market where strong insider alignment and clear strategic hires are rewarded, while sudden departures and lack of succession planning create material uncertainty.

23 high priority 23 total filings
· daily

USA Insider Trading Pulse — August 13, 2026

Today's insider trading pulse reveals a pronounced dichotomy: aggressive insider buying at deeply discounted valuations in Embecta Corp. and Amrize Ltd. contrasts with massive, pre-planned selling by Sea Ltd's entire C-suite totaling over $52 million. The data shows a clear sector rotation, with insiders at financial and industrial firms like Global Medical REIT and Blue Bird Corp signaling confidence, while technology and specialty finance executives, particularly at Camtek and Associated Banc-Corp, are reducing exposure. A notable cluster of 10% owner selling in Tredegar Corp by three family members suggests coordinated estate planning or a bearish outlook on the packaging sector. The most actionable signal is the coordinated insider buying spree at Amrize Ltd, where six executives purchased shares on the same day, indicating strong internal conviction. Overall, the data points to a market where insiders are betting on value and turnaround stories while taking profits in high-growth and cyclical names.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 13, 2026

This digest covers 11 SEC filings related to M&A and SPAC activity, revealing a bifurcated market. On one side, two major industrial acquisitions closed: Parker-Hannifin's $9.25B purchase of Filtration Group, funded with $7.75B in new debt, and Global Net Lease's $535M acquisition of Modiv Industrial, which is expected to be immediately accretive. These signal continued appetite for scale and strategic consolidation. Conversely, the SPAC sector shows significant distress: Artius II Acquisition Corp. announced liquidation, while several other SPACs (Athena Technology, Digital Asset Acquisition, Inflection Point) filed extensions or terminated agreements, highlighting a challenging environment for de-SPAC transactions. A key risk flag is NOCERA, INC., which filed an 8-K indicating a change in control and potential delisting, suggesting a distressed sale. The overall theme is a divergence between high-quality, accretive M&A and struggling blank-check companies facing liquidation or deal failure.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 13, 2026

Overnight filings reveal a bifurcated market with aggressive growth stories in niche sectors (BBB Foods, Elmet Group) offset by deep value destruction in biotech and SPACs. A massive coordinated insider sell-off at Takeda Pharmaceutical ($7.5M+ across 10 executives) signals deep concern within the C-suite, while a contrarian insider buying spree at Hepion Pharmaceuticals ($725K) suggests a potential turnaround play. The most significant capital event is SoundHound AI's proposed acquisition of LivePerson, which could reshape the conversational AI landscape. Key period-over-period trends show revenue growth is not translating to profitability, with 4 out of 5 reporting companies showing widening net losses despite top-line expansion. The energy sector shows mixed signals with enCore Energy's uranium deliveries up 38.6% but extraction costs soaring, while the SPAC market shows continued distress with Newbury Street's net income collapsing 81.5%.

40 high priority 10 medium 50 total filings
· daily

DHS Homeland Security Contracts — August 12, 2026

This digest covers a single $105.6 million civilian contract from the Department of Homeland Security (DHS) to Jacobs Engineering Group Inc. (parent STG LLC) for construction management advisory services on 11 border patrol station projects. The contract is entirely civilian, with no defense exposure, and signals sustained DHS investment in border security infrastructure under current immigration enforcement priorities. The highest-conviction signal is neutral: the firm-fixed-price structure provides revenue visibility but carries execution risk on 11 design-build projects. Key watch items include option exercises that could expand the contract to $162.3 million and potential policy shifts affecting DHS border funding.

1 total filings
· daily

VA Healthcare & Services Contracts — August 12, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) to Leidos Holdings (via QTC Medical Services) valued at $113.9 million for medical disability examinations. The contract is entirely civilian, with no defense-related exposure, and carries a strong bullish signal due to its firm-fixed-price structure and 92% outlay rate, indicating near-complete revenue realization and low execution risk. The highest-conviction signal is Leidos' competitive win under full-and-open competition, reinforcing its moat in VA medical evaluation services. A key risk is the single-contract concentration on Leidos, which creates dependency on VA's stable but non-growing budget for this mandated service line.

1 total filings
· daily

New Federal Contractors — August 12, 2026

This digest covers $615.8 million in new federal contract obligations from August 12, 2026, with a 1/4 defense-related split (the DHS/CBP award to Jacobs Engineering is the closest to defense, given border security alignment). The dominant sector theme is civilian healthcare and administrative services, led by Palmetto GBA's $212.5M CMS contract (low outlay raises execution questions) and Roche's $183.8M BARDA R&D award (cost-no-fee limits margin). The highest-conviction signal is Leidos' QTC Medical Services $113.9M VA disability exam contract, with 92% outlay indicating near-complete revenue realization and strong competitive positioning. Key risk: Palmetto GBA's contract expires September 2024 with only 7% disbursed, signaling potential funding stagnation or re-compete vulnerability.

4 total filings
· daily

Significant Contract Modifications ($10M+) — August 12, 2026

This digest covers four significant contract modifications totaling $615.8 million, with only one of four being defense-related (the Department of Homeland Security award to Jacobs Engineering), indicating a civilian-heavy procurement period. The dominant sector theme is healthcare and social services, with two large HHS awards (Palmetto GBA at $212.5M and Roche at $183.8M) and a VA award to Leidos (QTC Medical Services) at $113.9M. The highest-conviction signal is the bullish VA award to Leidos, where 92% of the $113.9M has already been outlaid, reflecting strong execution and stable demand. A key risk is the large outlay gap in the Palmetto GBA contract ($212.5M obligated but only $14.6M outlaid), which may signal execution or funding issues ahead of its September 2024 expiration.

4 total filings